Those prospective parturients that express that they may want an epidural labour analgesia for their delivery will be informed about the possibility to choose between a pump driven epidural or midwife administered intermittent boluses.

Start Date01 Dec 2024

Sponsor / Collaborator

Helsinki University Central Hospital

NCT06270407 / RecruitingPhase 4IIT

The Effect of Topical Tranexamic Acid on Postoperative Complications in Soft Tissue Plastic Surgery. a Multicenter Randomized Controlled Trial

Study objective:
This is a study to investigate whether applying the drug tranexamic acid (TXA) onto a surgical wound surface may affect the incidence of surgical complications such as re-bleeding needing intervention, wound complications such as infection, wound rupture or seroma, or if it may increase the risk of blood clots.
Eligible patients:
Patients undergoing plastic surgical procedures with wounds that would normally receive application of TXA to reduce bleeding after surgery.
Study intervention:
Participants will receive a single local application of study drug onto their wound surfaces at the end of surgery. Study drug will be identical looking ampoules which contain either TXA or placebo (saline). Neither participants nor study personnel will know the contents of the ampoules.

Start Date01 Oct 2024

Sponsor / Collaborator

St. Olavs Hospital hf

[+8]

NCT06650085 / Not yet recruitingNot ApplicableIIT

PROtective IleoStomy Versus ProtectivE Colostomy in Anterior Rectal ResectIon - a Multicenter, Open-label, Randomized ConTrolled StudY (PROSPERITY)

Loop ileostomy and loop colostomy are both used as protective stomas after anterior resection. There is a lack of evidence on the superiority of loop ileostomy versus loop colostomy. This is a multicenter, open-label, superiority, individually randomized controlled trial including patients undergoing anterior rectal resection with primary anastomosis and a protective stoma. Patients scheduled for anterior rectal resection are randomized 1:1 to loop ileostomy or loop colostomy intraoperatively. Primary outcome is cumulative stoma-related adverse events within 60 days post-primary surgery (scored using Comprehensive Complication Index (CCI)).

Start Date01 Oct 2024

Sponsor / Collaborator

Helsinki University Central Hospital

100 Clinical Results associated with Helsinki University Central Hospital

0 Patents (Medical) associated with Helsinki University Central Hospital

20,239

Literatures (Medical) associated with Helsinki University Central Hospital

31 Dec 2024·OncoImmunology

Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses

Article

Author: Lehtiö, Janne ; Branca, Rui M. ; Pietiäinen, Vilja ; Fusciello, Manlio ; Hamdan, Firas ; Sandberg, Janita ; Cerullo, Vincenzo ; Välimäki, Katja ; Malmstedt, Minna ; Stigzelius, Virpi ; Partanen, Jukka ; Rannikko, Antti ; Russo, Salvatore ; Clancy, Jonna ; Grönholm, Mikaela ; Feola, Sara ; Bottega, Paolo ; D´alessio, Federica ; Pellinen, Teijo ; Chiaro, Jacopo ; Feodoroff, Michaela ; Antignani, Gabriella

Immunotherapy has emerged as a promising approach for cancer treatment, with oncolytic adenoviruses showing power as immunotherapeutic agents. In this study, we investigated the immunotherapeutic potential of an adenovirus construct expressing CXCL9, CXCL10, or IL-15 in clear cell renal cell carcinoma (ccRCC) tumor models. Our results demonstrated robust cytokine secretion upon viral treatment, suggesting effective transgene expression. Subsequent analysis using resistance-based transwell migration and microfluidic chip assays demonstrated increased T-cell migration in response to chemokine secretion by infected cells in both 2D and 3D cell models. Flow cytometry analysis revealed CXCR3 receptor expression across T-cell subsets, with the highest percentage found on CD8+ T-cells, underscoring their key role in immune cell migration. Alongside T-cells, we also detected NK-cells in the tumors of immunocompromised mice treated with cytokine-encoding adenoviruses. Furthermore, we identified potential immunogenic antigens that may enhance the efficacy and specificity of our armed oncolytic adenoviruses in ccRCC. Overall, our findings using ccRCC cell line, in vivo humanized mice, physiologically relevant PDCs in 2D and patient-derived organoids (PDOs) in 3D suggest that chemokine-armed adenoviruses hold promise for enhancing T-cell migration and improving immunotherapy outcomes in ccRCC. Our study contributes to the development of more effective ccRCC treatment strategies by elucidating immune cell infiltration and activation mechanisms within the tumor microenvironment (TME) and highlights the usefulness of PDOs for predicting clinical relevance and validating novel immunotherapeutic approaches. Overall, our research offers insights into the rational design and optimization of viral-based immunotherapies for ccRCC.

31 Dec 2024·Journal of Oral Microbiology

Shotgun metagenomic analysis of the oral microbiome in gingivitis: a nested case-control study

Article

Author: Könönen, Eija ; Lahti, Leo ; Sinisalo, Juha ; Martinez-Majander, Nicolas ; Pussinen, Pirkko J ; Paju, Susanna ; Putaala, Jukka ; Pietiäinen, Milla ; Niiranen, Teemu ; Leskelä, Jaakko ; Manzoor, Muhammed

BackgroundGingivitis, i.e. inflammation of the gums, is often induced by dentalplaque. However, its exact link to the oral microbiota remains unclear.MethodsIn a case-control study involving 120 participants, comprising 60 cases and 60 controls (mean age (SD) 36.6 (7.6) years; 50% males), nested within a prospective multicentre cohort study, we examined theoral microbiome composition of gingivitis patients and their controlsusing shotgun metagenomic sequencing of saliva samples. Participants underwent clinical and radiographic oral health examinations, including bleeding on probing (BOP), at six tooth sites. BOP ≥33%was considered 'generalized gingivitis/initial periodontitis'(GG/IP), and BOP <33% as 'healthy and localized gingivitis'(H/LG). Functional potential was inferred using HUMANn3.ResultsGG/IP exhibited an increase in the abundance of Actinomyces, Porphyromonas, Aggregatibacter, Corynebacterium, Olsenella, and Treponema, whereas H/LG exhibited an increased abundance of Candidatus Nanosynbacter. Nineteen bacterial species and fourmicrobial functional profiles, including L-methionine, glycogen, andinosine-5'-phosphate biosynthesis, were associated with GG/IP. Constructing models with multiple markers resulted in a strong predictive value for GG/IP, with an area under the curve (ROC) of 0.907 (95% CI: 0.848-0.966).ConclusionWe observed distinct differences in the oral microbiome between the GG/IP and H/LG groups, indicating similar yet unique microbial profiles and emphasizing their potential role in progression of periodontal diseases.

31 Dec 2024·Annals of Medicine

Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study

Article

Author: Niemi, Mikko ; Aro, Aapo L ; Putaala, Jukka ; Teppo, Konsta ; Mustonen, Pirjo ; Lehtonen, Ossi ; Luojus, Alex ; Linna, Miika ; Hartikainen, Juha ; Kinnunen, Janne ; Tiili, Paula ; Kouki, Elis ; Halminen, Olli ; Itäinen-Strömberg, Saga ; Haukka, Jari ; Airaksinen, K E Juhani ; Lehto, Mika

BACKGROUNDLittle is known how individual time-in-therapeutic-range (TTR) impacts the effectiveness and safety of warfarin therapy compared to direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF).OBJECTIVETo compare the effectiveness and safety of standard dose DOACs to warfarin in patients with AF, while categorizing warfarin treated patients into quartiles based on their individual TTR.MATERIALS AND METHODSWe conducted a nationwide study including all patients with new-onset AF between 2011 and 2018 in Finland. Hazard ratios (HR) were calculated using Cox regression analysis with the inverse probability of treatment weighted method to assess the risks of ischaemic stroke (IS), intracranial haemorrhage (ICH) and mortality for users of apixaban (n = 12,426), dabigatran (n = 4545), rivaroxaban (n = 12,950) and warfarin (n = 43,548).RESULTSThe median TTR for warfarin users was 72%. Compared to the second best TTR quartile (reference), the risk of IS was higher in the two poorest TTR quartiles, and lower in the best TTR quartile and on rivaroxaban [2.35 (95% confidence interval, 1.85-2.85), 1.44 (1.18-1.75), 0.60 (0.47-0.77) and 0.72 (0.56-0.92)]. These differences were non-significant for apixaban and dabigatran. HR of ICH was 6.38 (4.88-8.35) and 1.87 (1.41-2.49) in the two poorest TTR groups, 1.44 (1.02-1.93) on rivaroxaban, and 0.58 (0.40-0.85) in the best TTR group compared to the reference group. Mortality was higher in the two poorest TTR groups and lowest in the best TTR group.CONCLUSIONSThe outcome was unsatisfactory in the two lowest TTR quartiles - in half of the patients treated with warfarin. The differences between the high TTR groups and standard dose DOACs were absent or modest.

News (Medical) associated with Helsinki University Central Hospital

17 Oct 2024

·www.prnewswire.com

Nikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor Cells

Celebrating its golden anniversary, Nikon Small World honors a stunning photo of brain tumor cell structures, advancing our understanding of neurodegenerative diseases. MELVILLE, N.Y., Oct. 17, 2024 /PRNewswire/ -- Nikon Instruments Inc. today announced the winners of the 50th annual Nikon Small World Photomicrography Competition, celebrating five decades of excellence in microscopy and digital imaging. This year's first place prize was awarded to Dr. Bruno Cisterna, with assistance from Dr. Eric Vitriol of Augusta University, for his groundbreaking image of differentiated mouse brain tumor cells, highlighting the actin cytoskeleton, microtubules, and nuclei. This image reveals how disruptions in the cell's cytoskeleton – the structural framework and "highways" known as microtubules – can lead to diseases like Alzheimer's and ALS. Continue Reading Differentiated mouse brain tumor cells (actin, microtubules, and nuclei) Dr. Cisterna's research revealed that profilin 1 (PFN1), a protein crucial for building the cell's structure, plays a key role in maintaining the microtubule highways essential for cellular transport. When PFN1 or related processes are disrupted, these highways can malfunction, leading to cellular damage similar to what is observed in neurodegenerative diseases. "One of the main problems with neurodegenerative diseases is that we don't fully understand what causes them," said Dr. Cisterna. "To develop effective treatments, we need to figure out the basics first. Our research is crucial for uncovering this knowledge and ultimately finding a cure. Differentiated cells could be used to study how mutations or toxic proteins that cause Alzheimer's or ALS alter neuronal morphology, as well as to screen potential drugs or gene therapies aimed at protecting neurons or restoring their function." His patience and determination were crucial in capturing his image. "I spent about three months perfecting the staining process to ensure clear visibility of the cells. After allowing five days for the cells to differentiate, I had to find the right field of view where the differentiated and non-differentiated cells interacted. This took about three hours of precise observation under the microscope to capture the right moment, involving many attempts and countless hours of work to get it just right." The hard work behind this discovery underscores its significance, bringing researchers closer to answers that could potentially transform millions of lives. "After three years of research, we finally published our findings four months ago in the Journal of Cell Biology, and there's still more work to be done," said Dr. Cisterna. "I'm deeply passionate about scientific imaging; I've been following the Nikon Small World contest for about 15 years. It's an incredible contest that highlights the beauty of photomicrography but also inspires continued exploration and innovation in the field." Eric Flem, Senior Manager, CRM and Communications at Nikon Instruments, shares a similar perspective on the competition. "At 50 years, Nikon Small World is more than just an imaging competition – it's become a gallery that pays tribute to the extraordinary individuals who make it possible. They are the driving force behind this event, masterfully blending science and art to reveal the wonders of the microscopic world and what we can learn from it to the public." He went on to add, "Sometimes, we overlook the tiny details of the world around us. Nikon Small World serves as a reminder to pause, appreciate the power and beauty of the little things, and to cultivate a deeper curiosity to explore and question." Second place was awarded to Dr. Marcel Clemens for his image of an electrical arc between a pin and a wire, produced by applying a potential difference of 10,000 volts. Third place was awarded to Chris Romaine for his image of a cannabis plant leaf. The bulbous structures are trichomes, or hair-like plant appendages, and the bubbles inside are cannabinoid vesicles, fluid-filled, blister-like structures. In total, Nikon Small World recognized 87 photos out of thousands of entries from scientists and artists across the globe. The 2024 judging panel included: Adrian Coakley, Director of Photography at National Geographic Books Michelle S. Itano, Ph.D., Assistant Professor of Cell Biology and Physiology and Director of the Neuroscience Microscopy Core at the University of North Carolina at Chapel Hill Emily Petersen, Photography Managing Editor at Science Magazine Clare Waterman, Ph.D., Cell Biologist and Member of the National Academy of Sciences Jennifer C. Waters, Ph.D., Director of the Core for Imaging Technology & Education at Harvard Medical School Samantha Yammine, Ph.D., Neuroscientist and Science Communicator For additional information, please visit , or follow the conversation on Facebook, Twitter @NikonSmallWorld and Instagram @NikonInstruments. NIKON SMALL WORLD WINNERS 1st Place Dr. Bruno Cisterna & Dr. Eric Vitriol Medical College of Georgia at Augusta University Department of Neuroscience & Regenerative Medicine Augusta, Georgia, USA Differentiated mouse brain tumor cells (actin, microtubules, and nuclei) Super-Resolution 100X (Objective Lens Magnification) 2nd Place Dr. Marcel Clemens Verona, Veneto, Italy Electrical arc between a pin and a wire Image stacking for the pin and wire combined with long exposure for the electrical arcs 10X (Objective Lens Magnification) 3rd Place Chris Romaine Kandid Kush Port Townsend, Washington, USA Leaf of a cannabis plant. The bulbous glands are trichomes. The bubbles inside are cannabinoid vesicles. Image Stacking 20X (Objective Lens Magnification) 4th Place Dr. Amy Engevik Medical University of South Carolina Department of Regenerative Medicine & Cell Biology Charleston, South Carolina, USA Section of a small intestine of a mouse Fluorescence 10X (Objective Lens Magnification) 5th Place Thomas Barlow & Connor Gibbons Columbia University Department of Neurobiology and Behavior New York, New York, USA Cluster of octopus (Octopus hummelincki) eggs Darkfield, Stereomicroscopy, Focus Stacking 3X (Objective Lens Magnification) 6th Place Henri Koskinen Helsinki University Helsinki, Uudenmaan lääni, Finland Slime mold (Cribraria cancellata) Image Stacking, Polarized Light, Reflected Light 10X (Objective Lens Magnification) 7th Place Gerhard Vlcek Maria Enzersdorf, Austria Cross section of European beach grass (Ammophila arenaria) leaf Brightfield, Image Stacking 10X (Objective Lens Magnification) 8th Place Stephanie Huang Victoria University of Wellington School of Biological Sciences; School of Psychology Wellington, New Zealand A neuron densely covered in dendritic spines from the striatum of an adult rat brain Confocal, Deconvolution, Image Stacking 60X (Objective Lens Magnification) 9th Place John-Oliver Dum Medienbunker Produktion Bendorf, Rheinland Pfalz, Germany Pollen in a garden spider (Araneus) web Image Stacking 20X (Objective Lens Magnification) 10th Place Jan Martinek Charles University Department of Experimental Plant Biology Prague, Czech Republic Spores of black truffle (Tuber melanosporum) Confocal 63X (Objective Lens Magnification) 11th Place Dr. Ferenc Halmos Bánd, Veszprém, Hungary Slime mold on a rotten twig with water droplets Image Stacking 0.7X - 4.5X (Objective Lens Magnification) 12th Place Daniel Knop Oberzent-Airlenbach, Hessen, Germany Wing scales of a butterfly (Papilio ulysses) on a medical syringe needle Image Stacking 20X (Objective Lens Magnification) 13th Place Paweł Błachowicz Bedlno, Świętokrzyskie, Poland Eyes of green crab spider (Diaea dorsata) Image Stacking, Reflected Light 20X (Objective Lens Magnification) 14th Place Marek Miś Marek Miś Photography Suwalki, Podlaskie, Poland Recrystallized mixture of hydroquinone and myoinositol Polarized Light 10X (Objective Lens Magnification) 15th Place Sébastien Malo Saint Lys, Haute-Garonne, France Isolated scales on Madagascan sunset moth wing (Chrysiridia ripheus) Darkfield, Image Stacking, Reflected Light 40X (Objective Lens Magnification) 16th Place Marek Miś Marek Miś Photography Suwalki, Podlaskie, Poland Two water fleas (Daphnia sp.) with embryos (left) and eggs (right) Darkfield, Polarized Light 10X (Objective Lens Magnification) 17th Place Dr. Frantisek Bednar Svosov, Zilinsky, Slovak Republic Stonewort algae (Chara virgata) reproductive organs - oogonia (female organs) and antheridia (male organs) Darkfield 4X (Objective Lens Magnification) 18th Place Alison Pollack San Anselmo, California, USA An insect egg parasitized by a wasp Image Stacking, Reflected Light 10X (Objective Lens Magnification) 19th Place Alison Pollack San Anselmo, California, USA Seed of a Silene plant Image Stacking, Reflected Light 10X (Objective Lens Magnification) 20th Place Dr. Bruno Cisterna & Dr. Eric Vitriol Medical College of Georgia at Augusta University Department of Neuroscience & Regenerative Medicine Augusta, Georgia, USA Early stage of mouse neuroblastoma cell differentiation (actin, microtubules, and mitochondria) Super-Resolution 100X (Objective Lens Magnification) HM Christopher Algar Hounslow, Middlesex, United Kingdom Brine shrimp Darkfield, Image Stacking, Polarized Light 4X (Objective Lens Magnification) HM Dr. Kseniia Bondarenko University of Edinburgh Institute for Immunology and Infection Research Edinburgh, MidLothian, United Kingdom Acute-stage parasites of Toxoplasma gondii in a human skin cell Expansion Microscopy, Confocal, Deconvolution 100X (Objective Lens Magnification) HM Dr. Anja de Lange University of Cape Town Neuroscience Institute & Department of Human Biology Cape Town, Western Cape, South Africa Astrocytes surrounding a blood vessel in a thin slice of human brain Confocal 40X (Objective Lens Magnification) HM Dr. Amy Engevik Medical University of South Carolina Department of Regenerative Medicine & Cell Biology Charleston, South Carolina, USA Intestinal villi Fluorescence 20X (Objective Lens Magnification) HM Daniel Evrard Aywaille, Liege, Belgium Vinyl player needle on scratched vinyl disk Image Stacking, Polarized Light 20X (Objective Lens Magnification) HM Randy Fullbright Fullbright Studio Vernal, Utah, USA Agatized dinosaur bone Image Stacking 10X (Objective Lens Magnification) HM Dr. David Maitland St. Andrews, Fife, United Kingdom Transverse section of rachis (stem) of bracken fern (Pteridium aquilinum) Differential Interference Contrast (DIC) 5X (Objective Lens Magnification) HM Angus Rae Australian National University Centre for Advanced Microscopy MacGregor, Australian Capital Territory, Australia Autofluorescence in the face of a little two-spotted ladybird (Diomus notescens) Fluorescence lifetime imaging microscopy (FLIM) 20X (Objective Lens Magnification) HM Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Antenna of a mole crab Confocal 10X (Objective Lens Magnification) HM Jochen Stern Mannheim, Baden-Wuerttemberg, Germany Golden bug eggs on a sage leaf Image Stacking 20X (Objective Lens Magnification) HM Dr. Bruce Douglas Taubert Glendale, Arizona, USA Ocelli between the compound eyes of a yellow jacket Reflected Light 10X (Objective Lens Magnification) HM Kevin Terretaz CRBM-CNRS Montpellier, Hérault, France Mosquito cells in culture with fluorescent markers for DNA and microtubules Confocal 63X (Objective Lens Magnification) IoD Dr. Sherif Abdallah Ahmed Tanta University, Faculty of Science Department of Zoology Tanta, Egypt, Arab Republic Anterior section of palm weevil Image Stacking 4X (Objective Lens Magnification) IoD Anne Patricia Algar Hounslow, Middlesex, United Kingdom Mosquito larva Darkfield, Image Stacking, Polarized Light 4X (Objective Lens Magnification) IoD Dr. Florian Alonso University of Bordeaux BioTis-INSERM U1026 Pessac, Gironde, France Mouse aortic endothelium stained for beta-catenin (green), laminin (purple), smooth muscle actin (red), and Hoechst (cyan) Confocal 63X (Objective Lens Magnification) IoD Didier Barbet Club Français de Microscopie Bailly, France Fracture surface of mica (mineral) Differential Interference Contrast (DIC) 10X (Objective Lens Magnification) IoD Timothy Boomer WildMacro.com Vacaville, California, USA Slime mold (Prototrichia metallica) Image Stacking 10X (Objective Lens Magnification) IoD Zhang Chao National Astronomical Observatories, Chinese Academy of Sciences Beijing, China Beach sand Reflected Light 10X (Objective Lens Magnification) IoD Joshua Coogler Dallas, North Carolina, USA Moss sporophyte with spores (green) Image Stacking 10X (Objective Lens Magnification) IoD Nikky Corthout & Miranda Dyson VIB (Flanders Institute of Biotechnology) Center for Brain and Disease Research Leuven, Vlaams-Brabant, Belgium Fruit fly (Drosophila) brain vasculature Confocal, Fluorescence, Image Stacking, Super-Resolution 25X (Objective Lens Magnification) IoD Nadia Efimova Amicus Therapeutics Philadelphia, Pennsylvania, USA Dandelion pappus Confocal, Fluorescence 20X (Objective Lens Magnification) IoD Dr. Laurent Formery & Dr. Nathaniel Clarke Stanford University Department of Molecular and Cell Biology Pacific Grove, California, USA Nervous system of a young sea star Confocal, Fluorescence 10X (Objective Lens Magnification) IoD Karl Gaff Dublin, Ireland Larva of a midge fly (Chironomidae) Darkfield, Image Stacking, Polarized Light 20X (Objective Lens Magnification) IoD Dr. Nick Gatford University of Oxford Nuffield Department of Clinical Neurosciences (NDCN) Oxford, Oxfordshire, United Kingdom A network of dopaminergic neurons generated from human stem cells Super-Resolution 63X (Objective Lens Magnification) IoD Dr. Saikat Ghosh National Institutes of Health NICHD Bethesda, Maryland, USA Human neurons Confocal 40X (Objective Lens Magnification) IoD Gerd A. Günther Düsseldorf, Germany Cross section of a beach grass (Ammophila arenaria) leaf Fluorescence 20X (Objective Lens Magnification) IoD Anna-Mari Elisabeth Haapanen-Saaristo University of Turku Turku Bioscience Centre / Cell Imaging & Cytometry Core and Zebrafish Core RAISIO, Varsinais-Suomi, Finland Nutrient storage cells in a tardigrade Confocal 25X (Objective Lens Magnification) IoD Dr. Martin Hein Lions Eye Institute Physiology and Pharmacology laboratory Nedlands, Western Australia, Australia Abnormal blood vessel formation in a human retina with severe diabetic retinopathy Confocal 20X (Objective Lens Magnification) IoD Wen Jie Ji Yin Works The Bureau of Microworld Exploration Beijing, China Integrated circuit chip Reflected Light 10X (Objective Lens Magnification) IoD Ted Kinsman Rochester Institute of Technology Photosciences Department Rochester, New York, USA A common house cat claw Polarized Light 10X (Objective Lens Magnification) IoD Daniel Knop Oberzent-Airlenbach, Hessen, Germany Opening of a hibiscus flower (Hibiscus moscheutos) exposing the pollen in four stages, each ten minutes apart Image Stacking 20X (Objective Lens Magnification) IoD Daniel Knop Oberzent-Airlenbach, Hessen, Germany Dorsal part of cuckoo wasp (Hedychrum gerstaeckeri) abdomen Image Stacking 20X (Objective Lens Magnification) IoD Dr. Håkan Kvarnström Bromma, Sweden Peacock plume feather Epi-Illumination, Image Stacking 4X (Objective Lens Magnification) IoD Dr. Ewa Langner Washington University in St Louis Department of Medicine - Renal Division, Mahjoub Lab St Louis, Missouri, USA Mouse embryonic kidney showing interstitial fibroblasts (yellow), tubular epithelium (cyan), and nuclei (magenta) Confocal, Fluorescence, Image Stacking 40X (Objective Lens Magnification) IoD Dr. Amir Maqbool Lovely Professional University Department of Zoology Srinagar, Jammu and Kashmir, India Small fly killed by "zombie fly" fungus (Entomophthora muscae) Image Stacking 2X (Objective Lens Magnification) IoD Dr. Robert Markus University of Nottingham School of Life Sciences, Super Resolution Microscopy Nottingham, Nottinghamshire, United Kingdom Dandelion (Traxacum officinale) cross section showing curved stigma with pollen Confocal 10X (Objective Lens Magnification) IoD Dr. Robert Markus, Dr. Zeeshan Mohammad, Dr. Sarah Pashley & Dr. Rita Tewari University of Nottingham School of Life Sciences, Super Resolution Microscopy Nottingham, Nottinghamshire, United Kingdom Malaria parasites and mouse blood cells - tubulin (green), all proteins (purple), DNA (red) Confocal 63X (Objective Lens Magnification) IoD Jan Martinek Charles University Department of Experimental Plant Biology Prague, Czech Republic Spores of a black Bagnoli truffle (Tuber mesentericum) Confocal 63X (Objective Lens Magnification) IoD Dr. Guillermo Moya Johns Hopkins University Department of Biology Baltimore, Maryland, USA Neuronal axons connecting to the muscles of the iris and the cornea Confocal, Fluorescence 10X (Objective Lens Magnification) IoD Jacek Myslowski Wloclawek, Kujawko-Pomorskie, Poland Water mite (Arrenurus) Fluorescence, Image Stacking 6.3X (Objective Lens Magnification) IoD Aryah Nagarajan Falmouth University Institute of Photography Penryn, Cornwall, United Kingdom Spores releasing from the sori of a Polypody fern (Polypodium vulgare) Reflected Light, Transmitted Light, Focus Stacking 10X (Objective Lens Magnification) IoD Thomas Neumann Tübingen, Baden-Württemberg, Germany Ink dot on Japanese washi paper Brightfield, Image Stacking 20X (Objective Lens Magnification) IoD Satu Paavonsalo & Dr. Sinem Karaman University of Helsinki Individualized Drug Therapy Research Program, Faculty of Medicine, Helsinki, Finland Helsinki, Finland Blood vessels (color gradient) and endothelial cell nuclei (white) in the intestinal villi of a mouse Confocal 10X (Objective Lens Magnification) IoD Uwe Lange Hannover, Niedersachsen, Germany Pollen on the compound eyes of a fly Image Stacking 60X (Objective Lens Magnification) IoD Dr. Marko Pende MDI Biological Laboratory Murawala Lab Bar Harbor, Maine, USA Ladybug (Coccinellidae) on a clover (Trifolium repens) Confocal, Fluorescence, Image Stacking 4X (Objective Lens Magnification) IoD Dr. Felice Placenti FP Nature and Landscape Photography Siracusa, Sicilia, Italy Potato tuber sprout Image Stacking, Reflected Light 1X (Objective Lens Magnification) IoD Alison Pollack San Anselmo, California, USA Slime mold (Lamproderma arcyrioides) Image Stacking, Reflected Light 10X (Objective Lens Magnification) IoD Dr. Gonzalo Quiroga Artigas CRBM-CNRS Montpellier, Herault, France Tardigrade (Hypsibius exemplaris) Confocal 40X (Objective Lens Magnification) IoD Chris Romaine Kandid Kush Port Townsend, Washington, USA Bract (part of the plants reproductive structures) of a cannabis plant. The bulbous glands are trichomes. Image Stacking 20X (Objective Lens Magnification) IoD Dr. Adolfo Ruiz De Segovia PARTICULAR Madrid, Spain Plant root Fiber Optic 2X (Objective Lens Magnification) IoD Yurim Seo, Dr. Mark Looney & Dr. Simon Cleary University of California, San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine San Francisco, California, USA Lymphatic vasculature (cyan) and vessels (red) of a mouse lung Confocal 4X (Objective Lens Magnification) IoD Dr. Leo Serra University of Cambridge Sainsbury Laboratory Cambridge, Cambridgeshire, United Kingdom Leaves arising from thale cress (Arabidopsis thaliana) meristem Confocal 20X (Objective Lens Magnification) IoD Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Aster anther cross section with pollen grains (green) Confocal 40X (Objective Lens Magnification) IoD Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Floret of a common chicory with pollen grains (spiky balls) Confocal 40x (Objective Lens Magnification) IoD Luna Šošo Zdravković, Michael Surala & Christian Madry Charité Universitätsmedizin Berlin Institute of Neurophysiology Berlin, Germany Pyramidal neuron in mouse hippocampus Confocal, Fluorescence, Image Stacking 30X (Objective Lens Magnification) IoD Dr. Bruce Douglas Taubert Glendale, Arizona, USA Mid-tibial tuft on a male orchid bee, used to attract mates Reflected Light 10X (Objective Lens Magnification) IoD Maxime Teixeira Laval University Department of Molecular Medicine Québec, Canada Cultured monkey kidney cells labeled for tubulin (blue) and actin (orange) showing pathological accumulation of alpha-syn aggregates (red) Confocal, Deconvolution, Image Stacking, Super-Resolution 100X (Objective Lens Magnification) IoD Dr. Theo Theune Oost-Souburg, Zeeland, Netherlands Abdominal skin of a tick that engorged with blood Image Stacking 50X (Objective Lens Magnification) IoD Dr. Grigorii Timin & Dr. Michel Milinkovitch University of Geneva Department of Genetics and Evolution Geneva, Switzerland Skin scales of a snake embryo stained with Fast Green dye Confocal 63X (Objective Lens Magnification) IoD Steven A. Valley Oregon Department of Agriculture (ODA) Entomology Lab Albany, Oregon, USA Immature male damselfly (Calopteryx aequabilis) Image Stacking, Reflected Light 5X (Objective Lens Magnification) IoD Dr. Bruno Vellutini Max Planck Institute of Molecular Cell Biology and Genetics Dresden, Saxony, Germany Gene expression patterns in a drain fly embryo (Clogmia albipunctata) with an open eggshell Confocal 20X (Objective Lens Magnification) IoD Susannah Waxman & Dr. Ian Sigal University of Pittsburgh Department of Ophthalmology Pittsburgh, Pennsylvania, USA Optic nerve head collagen of a pig Image Stacking, Multiphoton 25X (Objective Lens Magnification) IoD Shao Yang Beijing Miteyide Culture Co., Ltd. Beijing, China Fiber of nylon stockings Polarized Light 5X (Objective Lens Magnification) IoD Chew Yen Fook Woodend, Waimakiriri, New Zealand Graffiti from Berlin Wall stone section Image Stacking, Top Illumination 10X (Objective Lens Magnification) IoD Chew Yen Fook Woodend, Waimakiriri, New Zealand Water mite (Hydrachna sp.) Darkfield, Image Stacking, Polarized Light 20X (Objective Lens Magnification) IoD Elkhan Yusifov & Dr. Martina Schaettin University of Zurich Department of Molecular Life Sciences Zurich, Switzerland Developing nervous system in the eye of a 7-day-old chick embryo Stereomicroscopy 10X (Objective Lens Magnification) IoD Ou Zhilei Guangdong Radio and Television Guangzhou, Guagndong, China Stamens of flowers (Anemone cathayensis Kitag. ex Ziman & Kadota) Image Stacking 10X (Objective Lens Magnification) About Nikon Small World Photomicrography Competition The Nikon Small World Competition is open to anyone with an interest in photography or video. Participants may upload digital images and videos directly at . For additional information, contact Nikon Small World, Nikon Instruments Inc., 1300 Walt Whitman Road, Melville, NY 11747, USA, or phone (631) 547-8569. Entry forms for Nikon's 2025 Small World and Small World in Motion Competitions are available at . About Nikon Instruments Inc. Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacturing of optical, digital imaging technology and software for biomedical applications. For more information, please visit or contact us at 1-800-52-NIKON. SOURCE Nikon Instruments Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

08 Oct 2024

·www.globenewswire.com

MONCYTE Health Raises EUR 1 Million Seed Capital to Advance Personalized Treatment for High Cholesterol

HELSINKI, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MONCYTE Health diagnostics, developing proprietary technology to optimize treatment and prevention of cardiovascular disease, has closed a EUR 1 million seed round to fund its go-to-market strategy. Its technology is designed to help clinicians select more effective personalized treatments for patients with high cholesterol. The round was led by Finnish venture capital investors Inventure, Almaral, and Athensmed and included funding from University of Helsinki Funds, private European investors, and a grant from Business Finland. Cardiovascular disease is the primary cause of death worldwide, with high cholesterol being one of most important risk factors of the disease. High blood cholesterol can lead to the formation of atherosclerotic plaques, which are fat deposits in arterial walls that can block the blood flow and lead to heart attack and stroke. Currently, a significant proportion of high-risk patients do not achieve optimal blood cholesterol levels and remain at elevated risk for cardiovascular disease. MONCYTE Health has a unique proprietary technology to quantify individual differences in cellular lipid uptake and storage which contribute to high blood cholesterol and the effectiveness of common lipid-lowering drugs. The readouts are derived from white blood cells, including monocytes, which play key roles in atherosclerotic plaque formation and inflammation, linking directly to cardiovascular risk. Precisely quantifying these individual differences enables personalized treatment strategies in combination with risk assessment which can help patients more effectively achieve optimal blood cholesterol levels faster, and thereby reduce the risk for cardiovascular disease. The technology also provides insight for pharmaceutical companies about how novel lipid-lowering drugs influence the cellular processes contributing to cardiovascular risk. “Over 1.5 billion people world-wide are affected by high cholesterol. Our technology focuses on how cholesterol is transported and processed in human cells, and since the most important cholesterol-lowering treatments function at the cellular level, this type of technology is essential to disease understanding and identifying opportunities for developing novel drugs and personalized therapies for high cholesterol”, said Tamara Alagirova, CEO and co-founder at MONCYTE Health. “We are extremely happy to receive this funding, which will support the development of our unique diagnostic technology and can make a real difference in improving health. We believe that personalized approaches for more effective lipid-lowering therapy and better insights into how immune cells accelerate plaque development can prevent heart attack and stroke more effectively.” “Investing in MONCYTE Health was a compelling choice for us, driven by the exceptional expertise of the team and initial traction of the market. We are excited to embark on this journey together and make an impact,” said Maria Severina, CEO and Founder at Almaral. “MONCYTE Health is laser focused on high cholestrol, the leading risk factor for cardiovascular diseases. The team, led by Tamara and CSO and co-founder, Simon Pfisterer, has spent years in Helsinki University in creating a unique technology, IP, and deep understanding in cellular mechanisms underlying cardiovascular disease progression. With this investment, we are excited to help support taking this innovative technology to the market, in close co-operation with major pharmaceutical companies and health clinics. We will leverage our strong networks to support MONCYTE Health in enhancing its global footprint and driving further success,” said Sami Lampinen, Founding Partner at Inventure. “We see that MONCYTE Health’s innovation is a great leap in the treatment of high cholesterol, which is a major public health challenge. We invest in companies, where great health benefits meet great business opportunities, and there is a superior team capable of executing the plan,” said Kustaa Piha, CEO and Founder of Athensmed. MONCYTE Health’s technology is significantly different from other diagnostic tests. Rather than quantify biomarkers which are present in blood, MONCYTE Health quantifies the cellular processes that affect the biomarkers. This unique insight provides the possibility to predict an optimal treatment strategy and to overcome current approaches of trying out different medications over time. For additional information: Tamara Alagirova, CEO & co-founder ta@moncyte.com http://www.moncytehealth.com For Media Scius Communications Katja Stout +44 7789 435990 katja@sciuscommunications.com Daniel Gooch +44 7747 875479 Daniel@sciuscommunications.com About MONCYTE Health MONCYTE Health diagnostics is developing pioneering technology that provides quantitative insight into the biological processes that give rise to high blood cholesterol and how they are different in individuals. MONCYTE Health provides new data for clinical use and enables novel readouts for pharmaceutical companies developing lipid-lowering treatments. In 2024 it raised a seed round of EUR 1 million, from Finnish venture capital investors Inventure, Almaral, and Athensmed including funding from University of Helsinki Funds, private European investor, and a grant from Business Finland. The company is based in Helsinki, Finland. For more information, visit moncytehealth.com and follow us on LinkedIn. About Atherosclerosis Atherosclerosis is characterized by the accumulation of fatty deposits in artery walls. These fat deposits are called plaques. Plaques can grow, destabilize and rupture, resulting in an obstruction of the blood flow through the artery. If this happens in an artery supporting the heart it leads to a heart attack, if the artery supports the brain it results in a stroke. Heart attack and stroke are cardiovascular diseases. Elevated blood lipids, especially high cholesterol (LDL-cholesterol (low-density lipoprotein cholesterol)), cause the formation of atherosclerotic plaques and long-term exposure can lead to heart attack and stroke. Maintaining low levels of blood lipids is known to prevent the formation of atherosclerotic plaques and effective lipid-lowering therapy can reduce the burden of existing plaques. Plaque formation is associated with the recruitment of immune cells which play key roles in inflammation. Inflammation can accelerate the formation of atherosclerotic plaques and render plaques more prone to rupture. This might explain why some individuals have a higher risk for heart attack or stroke as compared to others.

17 Jun 2024

·www.prnewswire.com

Trustworthy and Responsible AI Network expands to help European healthcare organizations enhance the quality, safety and trustworthiness of AI in health

AMSTERDAM, June 17, 2024 /PRNewswire/ -- Monday, at HLTH Europe, the Trustworthy & Responsible AI Network (TRAIN), a consortium of healthcare leaders, announced its expansion to Europe with the objective to help organizations in the region operationalize responsible AI through technology-based guardrails. Organizations that have come together to form the European TRAIN include Erasmus MC (the Netherlands), HUS Helsinki University Hospital (Finland), Sahlgrenska University Hospital (Sweden), Skåne University Hospital (Sweden), Universita Vita-Salute San Raffaele (Italy), and University Medical Center Utrecht (the Netherlands), with Microsoft as the technology enabling partner. Foundation 29, a nonprofit organization that aims to empower patients and transform healthcare through data-driven initiatives and innovative technologies, has also joined European TRAIN. The network is open to other healthcare organizations in Europe interested in joining. Emerging AI technologies hold significant promise for revolutionizing the healthcare sector in Europe and across the globe. By enhancing patient care outcomes, streamlining processes and reducing costs, AI has the potential to transform the industry. As the technology continues to evolve, robust development and evaluation standards are crucial to ensure responsible and effective AI applications. TRAIN aims to improve the quality, safety and trustworthiness of AI tools implemented in healthcare to help ensure clinicians and patients benefit from this innovative technology. TRAIN's initial formation, announced in March 2024, introduced leading healthcare organizations in the U.S. as part of the network. The consortium's operational objectives include: Providing technology and tools that enable trustworthy and responsible AI principles to be operationalized at scale. Working in collaboration with other TRAIN members and key stakeholders to enable all organizations, including low-resource settings, to benefit from technology-based responsible AI guardrails. Sharing best practices related to the use of AI in healthcare settings, including the safety, reliability and monitoring of AI algorithms, and the skillsets required to manage AI responsibly. Data and AI algorithms will not be shared between member organizations or with third parties. Working toward enabling registration of AI used for clinical care or clinical operations through a secure online portal. Providing tools to enable measurement of outcomes associated with the implementation of AI, including best practices for studying the efficacy and value of AI methods in healthcare settings and leveraging of privacy-preserving environments, with considerations in both pre- and post-deployment settings. Tools that allow analyses to be performed in subpopulations to assess bias may also be provided. Working toward the development of a federated AI outcomes registry for organizations to share among themselves. The registry will capture real-world outcomes related to efficacy, safety and optimization of AI algorithms. For more information on European TRAIN, join us at HLTH Europe on Tuesday, June 18, from 12:30 to 12:40 p.m. CEST at The Forum stage (H90), where we'll share more details about the network and its objectives. TRAIN member quotes: "Transforming healthcare using AI must be seen as a global challenge that requires worldwide cross-border collaborations. This approach is an important step that enables us to tackle challenges not only at the national level, but also across the EU and globally. To truly warrant bedside adoption, we must work together to ensure AI benefits all. Safeguards built into the technology will improve such equity." — Dr. Michel van Genderen, attending intensivist at Erasmus Medical Center and co-founder of the Erasmus MC Datahub "As an NGO dedicated to researching the use of AI in healthcare, Foundation 29 is deeply concerned with ensuring that the use of AI respects patient privacy and security. While high-quality data, often sourced from patients, is essential for advancing AI technologies, it is equally crucial to guarantee responsible use of this data. For us, safeguarding patient data and fostering a trustworthy environment for AI development and deployment in healthcare is of paramount importance." — Sarah Harmon, president, Foundation 29 "AI has the potential to transform healthcare, but we must remain vigilant about its ethical implications. In TRAIN, we are joining forces across Europe to share knowledge and tools for successful and sustainable implementation of trustworthy and responsible AI into healthcare practices." — Magnus Kjellberg, head of AI Competence Center, Sahlgrenska University Hospital "TRAIN is a role model for joint efforts between the technology industry and healthcare. AI represents a strategy that gives hope for future healthcare effectiveness. The upcoming European TRAIN effort will be an opportunity to take a fundamental step forward to operationalize responsible AI solutions by facilitating the generation and validation of algorithms with patient integrity left intact." — Professor Stefan Jovings, M.D., Ph.D., president of research and education, Skane University Hospital, Sweden "TRAIN's focus on responsible AI principles and privacy-preserving collaboration enforces our strategies to safely and ethically leverage AI technologies. This initiative builds trust, protects patient data, and aligns the participating institutions' practices to the European healthcare standards." — Carlo Tacchetti, professor and coordinator, AI strategic program of UniSR and director of Experimental Imaging Center, San Raffaele Scientific Institute "AI in healthcare needs collaborations on a national and an international level to help us use AI's power for improving patient care and outcomes. We are excited to be part of this collaboration to contribute to the new era of medicine that awaits us." — Ben Collignon, chief information officer, UMC Utrecht "The primary goal for TRAIN is to enable individuals and organizations to operationalize responsible AI principles through technology-based guardrails. TRAIN will also enable organizations to collaborate through federated, privacy-preserving approaches. The formation of TRAIN in Europe will help foster trust and confidence in the application of AI in health and ensure that data privacy is maintained." — David Rhew, M.D., chief medical officer and vice president of healthcare, Microsoft About the Trustworthy & Responsible AI Network (TRAIN) The Trustworthy & Responsible AI Network (TRAIN) is one of the first health AI networks aimed at operationalizing responsible AI principles. Through collaboration, TRAIN members will help improve the quality, safety, and trustworthiness of AI in health by sharing best practices, enabling registration of AI used for clinical care or clinical operations, providing tools to enable measurement of outcomes associated with the implementation of AI, and facilitating the development of a federated AI outcomes registry for organizations to share amongst themselves. SOURCE Microsoft Corp.

100 Deals associated with Helsinki University Central Hospital

100 Translational Medicine associated with Helsinki University Central Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 27 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fecal Microbiota(Helsinki University Central Hospital)	Urinary Tract Infections More	Phase 3 Clinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis